|
melanoma
|
0.170 |
GeneticVariation
|
disease |
BEFREE |
Amelanotic/hypomelanotic melanoma was associated with TYR rs1126809*A/A [OR (CI 95%) 2.7 (1.1-6.8) vs. 1.2 (0.8-1.9)] and PLA2G6 rs11570734*A/A [OR (CI 95%) 3.7 (1.0-13.6) vs. 1.3 (0.9-2.0)].
|
30680790 |
2019 |
|
melanoma
|
0.170 |
GeneticVariation
|
disease |
BEFREE |
PLA2G6 rs132985*T was associated with BRAF V600E (OR = 1.32, 95% CI = 1.05-1.67) and BRAF other (OR = 1.82, 95% CI = 1.11-2.98), but not BRAF V600K or NRAS+ melanoma.
|
29753029 |
2018 |
|
melanoma
|
0.170 |
GeneticVariation
|
disease |
BEFREE |
In addition, we show that skin DNA methylation is associated in cis with known genome-wide association study single nucleotide polymorphisms for nevus count, at PLA2G6 (P = 1.7 × 10<sup>-49</sup>) and NID1 (P = 6.4 × 10<sup>-14</sup>), as well as melanoma risk, including in or near MC1R, MX2, and TERT/CLPTM1L (P < 1 × 10<sup>-10</sup>).
|
27993549 |
2017 |
|
melanoma
|
0.170 |
GeneticVariation
|
disease |
GWASCAT |
Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.
|
28212542 |
2017 |
|
melanoma
|
0.170 |
GeneticVariation
|
disease |
BEFREE |
The risk associations with 16 SNPs around DUSP14 (rs1051849) and a previous reported melanoma locus MAFF/PLA2G6 (proxy SNP rs4608623) were replicated in the GenoMEL dataset (P < 0.01) but failed in the Australian dataset.
|
23291271 |
2013 |
|
melanoma
|
0.170 |
GeneticVariation
|
disease |
GWASDB |
A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.
|
21706340 |
2012 |
|
melanoma
|
0.170 |
Biomarker
|
disease |
BEFREE |
A series of genome-wide association studies (GWASs) in 2008 and 2009 showed that a handful of additional genes (e.g., ASIP, TYR, and PLA2G6) influencing these endophenotypes also affected melanoma risk.
|
22475760 |
2012 |
|
melanoma
|
0.170 |
Biomarker
|
disease |
BEFREE |
We genotyped 1028 invasive case patients and 1469 controls for variants in methylthioadenosine phosphorylase (MTAP), phospholipase A2, group VI (PLA2G6), and Interferon regulatory factor 4 (IRF4), and compared allelic frequencies globally and by anatomical site and histological subtype of melanoma.
|
21962134 |
2011 |
|
melanoma
|
0.170 |
AlteredExpression
|
disease |
BEFREE |
In immortalized rat brain GP8.3 EC cultures, conditioned media (CM) prepared from SK-MEL28 and OCM-1 melanoma cells significantly enhanced arachidonic acid release, cytosolic phospholipase A(2) (cPLA(2)) and Ca(+)-independent phospholipase A(2) (iPLA(2)) specific activities, and cell growth by 24 h. Inhibitors such as wortmannin and LY294002 (vs. PI3 kinase activity), AACOCF(3), (vs. cPLA(2) and iPLA(2)), PD98059 (vs. ERK1/2 activity) and NS-398 (vs. cyclooxygenase-2 activity, COX-2) were all able to block cell proliferation and motility determined using a scratch wound healing assay in melanoma CMs-stimulated EC monolayers.
|
19747926 |
2009 |
|
melanoma
|
0.170 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies three loci associated with melanoma risk.
|
19578364 |
2009 |
|
melanoma
|
0.170 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study identifies three loci associated with melanoma risk.
|
19578364 |
2009 |